基质金属蛋白酶9及其组织抑制剂1与慢性阻塞性肺疾病的研究进展  

Research Progress on Matrix Metalloproteinase-9 and Tissue Inhibitor-1 with Chronic Obstructive Pulmonary Disease

作　　者：喻晶晶[1] 张勇[1] 何东初[1] 

机构地区：[1]广州军区武汉总医院中西医结合科,武汉430070

出　　处：《医学综述》2012年第1期28-30,共3页Medical Recapitulate

摘　　要：基质金属蛋白酶9(MMP-9)及基质金属蛋白酶抑制物1(TIMP-1)是调节细胞外基质降解合成的主要酶类,共同作用于呼吸道的细胞外基质和基底膜。目前认为,MMP-9/TIMP-1比值失衡与慢性阻塞性肺疾病(COPD)的发生、发展关系密切。抑制MMP-9的过度表达、调节MMP-9/TIMP-1平衡可以为COPD的发病机制和治疗提供新思路。同时,对高危人群进行COPD的易感基因检测,可能是未来预防治疗COPD的方向。现就近年来MMP-9/TIMP-1比值失衡与COPD关系的研究进展进行综述。Matrix metalloproteinase-9（MMP-9）and matrix metalloproteinase inhibitor-1（TIMP-1）are the main enzymes which regulate extracellular matrix degradation,and both of them operating on respiratory tract of extracellular matrix and basement membrane.Inhibition of MMP-9 overexpression and to adjust unbalanced MMP-9/TIMP-1 can provide new ideas for pathogenesis and treatment.Meanwhile,high-risk population for detection of chronic obstructive pulmonary disease（COPD）susceptibility gene,may be direction of prevention and treatment of COPD in the future.At present,unbalanced MMP-9/TIMP-1 is closely related to the occurrence and development of COPD.In this article,current progress in the research on the relationship between unbalanced MMP-9/TIMP-1 and COPD were reviewed for reference.

关 键 词：基质金属蛋白酶9 基质金属蛋白酶抑制物1 慢性阻塞性肺疾病 

分 类 号：R563.9[医药卫生—呼吸系统]